title: A retrospective analysis of VIOXX in Australia: using clinical trial data and linked administrative health data to predict patient groups at risk of an adverse drug event.
authors.forename: Margaret T
authors.initials: MT
authors.lastname: Whitstock
authors.forename: Christopher M
authors.initials: CM
authors.lastname: Pearce
authors.forename: Stephen C
authors.initials: SC
authors.lastname: Ridout
authors.forename: Elizabeth J
authors.initials: EJ
authors.lastname: Eckermann
mesh_terms: D016907:Adverse Drug Reaction Reporting Systems / Q000458:organization & administration; D000368:Aged; D000369:Aged, 80 and over; D001315:Australia; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data*; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects*; D016208:Databases, Factual; D005260:Female; D006801:Humans; D007783:Lactones / Q000009:adverse effects*; D016013:Likelihood Functions; D015233:Models, Statistical; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data*; D012189:Retrospective Studies; D018570:Risk Assessment; D013450:Sulfones / Q000009:adverse effects*
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib